This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Biotech Stock Mailbag: Spectrum Pharma

Last week, Discovery shares fell after the company released disappointing study results showing that its experimental drug Surfaxin failed to benefit children in acute respiratory failure.

Within days of that bad news, Discovery entered in a $35 million equity financing facility followed quickly by a $10 million stock offering at a steeply discounted price.

If you're unlucky enough to be a Discovery shareholder, you must be wondering what the hell is going on here? The "new" management team looks to be as incompetent and insensitive to shareholders as the old managers.

Discovery claims to be making progress with the FDA towards a first-quarter 2011 approval filing for the long-delayed Surfaxin as a treatment to prevent Respiratory Distress Syndrome in premature infants. What about Discovery inspires confidence that this goal can be achieved, especially considering the events of the past two weeks?

If and when Surfaxin is approved, I'd reconsider my bearish thesis in Discovery. Not one second sooner. If that means not catching the bottom, so be it. Too many investors have lost money thinking otherwise.


Joe A. writes, "Adam, what is your take on the recent delay from AspenBio Pharma (APPY - Get Report)? How long of a setback do you think this could be?"

One benefit of being a stock commentator and not an investor is that I get to read and laugh at disastrous news updates like the one posted by AspenBio last week without wincing in pain as my stock portfolio takes a hit. I'm sorry if that's what happened to you, Joe, but Aspen is ripe for mocking.

Aspen is being forced to delay a re-filing of its FDA approval application for the AppyScore appendicitis test because of "unexplained variability in results from site to site in the initial draft of the statistical analysis report," the company announced on June 7. The results come from a just-completed AppyScore phase III study.

"Unexplained variability" isn't explained in great detail but let's assume that Aspen has discovered an unacceptable level of variability in the accuracy of the AppyScore appendicitis test across the hospitals where the study was conducted.

6 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
GNBT $0.02 1.16%
APPY $0.56 15.00%
ARNA $4.69 -1.30%
DNDN $0.06 -6.02%
DSCO $1.60 -1.80%

Markets

DOW 18,192.46 -21.96 -0.12%
S&P 500 2,112.10 +1.36 0.06%
NASDAQ 4,982.0080 -5.8820 -0.12%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs